Qva149 Significantly Lowers The Rate And Risk Of Moderate Or Severe COPD Exacerbation Versus Salmeterol/fluticasone In Patients With Moderate To Severe COPD: The Lantern Study

被引：0
|
作者：
Zhong, N. [1 ]
Wang, C. [2 ]
Zhou, X. [3 ]
Zhang, N. [1 ]
Patalano, F. [4 ]
Humphries, M. [5 ]
Wang, L. [5 ]
Banerji, D. [6 ]
机构：
[1] Guangzhou Med Univ, Affiliated Hosp 1, State Key Lab Resp Dis, Guangzhou, Guangdong, Peoples R China
[2] Third Mil Med Univ, Inst Resp Dis, Xin Qiao Hosp, Chongqing, Peoples R China
[3] Third Mil Med Univ, Southwest Hosp, Dept Resp Med, Chongqing, Peoples R China
[4] Novartis Pharma AG, Basel, Switzerland
[5] Beijing Novartis Pharma Co Ltd, Shanghai, Peoples R China
[6] Novartis Pharmaceut, E Hanover, NJ USA
来源：
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE | 2015年 / 191卷
关键词：
D O I：
暂无
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
A3978
引用
收藏
页数：3
相关论文
共 50 条
  • [1] LANTERN: a randomized study of QVA149 versus salmeterol/fluticasone combination in patients with COPD
    Zhong, Nanshan
    Wang, Changzheng
    Zhou, Xiangdong
    Zhang, Nuofu
    Humphries, Michael
    Wang, Linda
    Thach, Chau
    Patalano, Francesco
    Banerji, Donald
    INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 2015, 10 : 1015 - 1026
  • [2] Efficacy And Safety Of Qva149 Compared With Salmeterol/fluticasone Combination In Chinese Patients With Moderate To Severe COPD: A Subgroup Analysis From The Lantern Study
    Zhong, N.
    Wang, C.
    Zhou, X.
    Zhang, N.
    Patalano, F.
    Humphries, M.
    Wang, L.
    Banerji, D.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2015, 191
  • [3] Efficacy and safety of QVA149 compared with salmeterol/fluticasone combination (SFC) in Chinese patients with moderate-to-severe COPD: A subgroup analysis from the LANTERN study
    Zhong, Nanshan
    Wang, Changzheng
    Zhou, Xiangdong
    Zhang, Nuofu
    Patalano, Francesco
    Humphries, Michael
    Wang, Linda
    Banerji, Donald
    EUROPEAN RESPIRATORY JOURNAL, 2015, 46
  • [4] EVALUATION OF EFFICACY AND SAFETY OF SWITCHING TO QVA149 FROM SALMETEROL/FLUTICASONE IN SYMPTOMATIC PATIENTS WITH MODERATE-TO-SEVERE COPD: THE FLASH STUDY
    Frith, Peter
    Riachy, Moussa
    Ditommaso, Shelley
    Fogel, Robert
    Pilipovic, Virginia
    RESPIROLOGY, 2015, 20 : 39 - 39
  • [5] CARDIO- AND CEREBROVASCULAR SAFETY OF QVA149 IN PATIENTS WITH MODERATE TO SEVERE COPD: A POOLED ANALYSIS
    Frith, P.
    Dahl, R.
    Buhl, R.
    Mezzi, K.
    Schubert-Tennigkeit, A.
    Chen, H.
    Banerji, D.
    Fogel, R.
    RESPIROLOGY, 2015, 20 : 81 - 81
  • [6] DUAL BRONCHODILATION WITH QVA149 IN PATIENTS WITH MODERATE-TO-SEVERE COPD: IGNITE TRIALS OVERVIEW
    Mezzi, Karen
    Fedele, Mark J.
    Chen, Hungta
    Banerji, Donald
    RESPIROLOGY, 2013, 18 : 69 - 69
  • [7] QVA149 reduces the risk of moderate-to-severe exacerbations compared with open-label tiotropium in patients with severe COPD: The SPARK study
    Wedzicha, Jadwiga A.
    Decramer, Marc
    Olsson, Petter
    Chen, Hungta
    Fogel, Robert
    Banerji, Donald
    EUROPEAN RESPIRATORY JOURNAL, 2014, 44
  • [8] QVA149 ONCE DAILY IMPROVES EXERCISE TOLERANCE AND LUNG FUNCTION IN PATIENTS WITH MODERATE TO SEVERE COPD: THE BRIGHT STUDY
    Beeh, K. M.
    Korn, S.
    Beier, J.
    Jadayel, D.
    Henley, M.
    Tylek, J.
    Berhane, I.
    D'Andrea, P.
    Banerji, D. Donald
    THORAX, 2012, 67 : A147 - A147
  • [9] Cardio- and cerebrovascular safety of QVA149 in patients with moderate-to-very severe COPD: A pooled analysis
    Dahl, Ronald
    Buhl, Roland
    Mezzi, Karen
    Schubert-Tennigkeit, Agnes
    Chen, Hungta
    Banerji, Donald
    Fogel, Robert
    EUROPEAN RESPIRATORY JOURNAL, 2014, 44
  • [10] Cardio- and cerebrovascular safety of QVA149 in patients with moderate-to-very severe COPD: A pooled analysis
    Dahl, Ronald
    Buhl, Roland
    Mezzi, Karen
    Schubert-Tennigkeit, Agnes
    Chen, Hungta
    Banerji, Donald
    Fogel, Robert
    EUROPEAN RESPIRATORY JOURNAL, 2014, 44
12345